Loading stock data…
CGEM
$13.43+0.38 (+2.91%)
Market ClosedLast close May 1
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cullinan Therapeutics, Inc. in the Healthcare sector is trading at $13.43. The stock is currently 20% below its 52-week high of $16.74, remaining 30.6% above its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why CGEM maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.43
Potential Upside
5%
Whystock Fair Value$14.10
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$31.63+135.5%
Range$24.00 – $38.00
Fundamentals
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune disease...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$837.68M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.11
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-50.59%
Volume
Today's trading volume
510,978
Recent News
Will Health Benefits Weakness Drag Elevance's Q1 Earnings?
ELV heads into its April 22 Q1 report with EPS likely down 11.4% as Health Benefits operating income is projected to plunge 13.7% year over year.
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data
Cullinan Therapeutics (NASDAQ:CGEM) outlined a milestone-heavy roadmap during a presentation at Leerink Partners’ Annual Healthcare Conference in Miami, with management emphasizing 2026 as a potentially “defining year” driven by multiple clinical readouts across its pipeline. Chief Executive Officer
Cullinan Therapeutics: Q4 Earnings Snapshot
CAMBRIDGE, Mass. AP) — Cullinan Therapeutics, Inc. CGEM) on Tuesday reported a loss of $50.7 million in its fourth quarter.
Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference
Cullinan Therapeutics (NASDAQ:CGEM) executives highlighted upcoming clinical milestones for the company’s two high-priority T-cell engager programs during remarks at the 46th Annual TD Cowen Healthcare Conference, pointing to multiple data readouts in autoimmune disease in 2026 and an expansion plan
Cullinan Therapeutics Touts 2026 “Defining Year” as T-Cell Engager, Zipalertinib Catalysts Near
Cullinan Therapeutics (NASDAQ:CGEM) executives highlighted multiple upcoming catalysts across the company’s oncology and autoimmune portfolio during a presentation at Citi’s Virtual Oncology Leadership Summit, with management calling 2026 a “defining year” for the company. CEO Nadim Ahmed and Chief